Apogee Therapeutics (APGE) Cash & Current Investments (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash & Current Investments data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Cash & Current Investments rose 106.48% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 106.48% YoY) and the FY2025 annual result came in at $730.2 million, up 40.25% from the prior year.
• Cash & Current Investments improved to $1.1 billion in Q1 2026 per APGE's latest filing, from $730.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.1 billion in Q1 2026 and bottomed at $5.0 million in Q2 2022.
• The 5-year median for Cash & Current Investments is $517.0 million (2024), against an average of $498.2 million.
• The widest annual swing landed in 2023, when Cash & Current Investments soared 2415.08%; it then slumped 37.11% in 2025.
• Tracing APGE's Cash & Current Investments over 5 years: stood at $151.9 million in 2022, then surged by 160.36% to $395.5 million in 2023, then soared by 31.66% to $520.7 million in 2024, then jumped by 40.25% to $730.2 million in 2025, then jumped by 45.15% to $1.1 billion in 2026.
• Per Business Quant, the three latest APGE Cash & Current Investments figures stand at $1.1 billion (Q1 2026), $730.2 million (Q4 2025), and $527.3 million (Q3 2025).

Peer Comparison